Integra LifeSciences Holdings Corporation $IART Shares Acquired by Systematic Financial Management LP

Key Points

• Systematic Financial Management LP increased its stake in Integra LifeSciences Holdings Corporation by 8.9%, acquiring an additional 76,271 shares, bringing its total ownership to approximately 1.21% of the company.
• Integra LifeSciences reported a Q2 earnings per share of $0.45, beating the consensus estimate of $0.43, and had revenue of $415.61 million, exceeding expectations of $395.06 million.
• JPMorgan Chase & Co. and Wells Fargo & Company both lowered their price targets on Integra LifeSciences significantly, reflecting cautious market sentiment around the stock.

Systematic Financial Management LP raised its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 8.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 936,834 shares of the life sciences company's stock after buying an additional 76,271 shares during the period. Systematic Financial Management LP owned about 1.21% of Integra LifeSciences worth $20,601,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Wellington Management Group LLP boosted its position in shares of Integra LifeSciences by 10.4% during the first quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock valued at $60,827,000 after buying an additional 259,987 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Integra LifeSciences by 2,418.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after buying an additional 1,728,480 shares during the period. Paradigm Capital Management Inc. NY boosted its position in shares of Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after buying an additional 901,600 shares during the period. Lord Abbett & CO. LLC boosted its position in shares of Integra LifeSciences by 86.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after buying an additional 618,773 shares during the period. Finally, Soleus Capital Management L.P. purchased a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $28,940,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IART. Wells Fargo & Company lowered their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities lowered their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $18.63.

Integra LifeSciences Stock Up 0.7%

NASDAQ:IART traded up $0.11 during trading hours on Wednesday, reaching $14.87. The company's stock had a trading volume of 2,333,305 shares, compared to its average volume of 1,044,087. The company has a market capitalization of $1.16 billion, a P/E ratio of -2.28, a price-to-earnings-growth ratio of 0.80 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The stock has a 50 day moving average price of $12.86 and a two-hundred day moving average price of $16.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The company had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences's revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.